Mar. Drugs 2016, 14, 84. S3 of S26. Figure S5. 13C-NMR spectrum of compound 1 (75 MHz in MeOH). Figure S6. 1H-NMR spectrum of compound 1 (300 MHz ...
Mar. Drugs 2016, 14, 84
S1 of S26
Supplementary Materials: Ergosterols from Culture Broth of a Marine Derived Streptomyces sp. H41-59 Yang-Mei Zhang, Hong-Yu Li, Chen Hu, Hui-Fan Sheng, Ying Zhang, Bi-Run Lin and Guang-Xiong Zhou Compound 1
Figure S1. UV spectrum of compound 1 in MeOH.
Figure S2. IR spectrum of compound 1.
Mar. Drugs 2016, 14, 84
S2 of S26
Figure S3. HR-TOF-MS of compound 1.
Figure S4. 1H-NMR spectrum of compound 1 (300 MHz in MeOH).
Mar. Drugs 2016, 14, 84
S3 of S26
Figure S5. 13C-NMR spectrum of compound 1 (75 MHz in MeOH).
Figure S6. 1H-NMR spectrum of compound 1 (300 MHz in DMSO-d6).
Mar. Drugs 2016, 14, 84
S4 of S26
Figure S7. 13C-NMR spectrum of compound 1 (75 MHz in DMSO-d6).
Figure S8. DEPT spectrum of compound 1 (75 MHz in DMSO-d6).
Mar. Drugs 2016, 14, 84
S5 of S26
Figure S9. COSY spectrum of compound 1 (600 MHz in DMSO-d6).
Figure S10. HMQC spectrum of compound 1 (600 MHz in DMSO-d6).
Mar. Drugs 2016, 14, 84
S6 of S26
Figure S11. HMBC spectrum of compound 1 (600 MHz in DMSO-d6).
Figure S12. NOESY spectrum of compound 1 (600 MHz in DMSO-d6).
Mar. Drugs 2016, 14, 84
S7 of S26
Compound 2
Figure S13. UV spectrum of compound 2 in MeOH.
Figure S14. IR spectrum of compound 2.
Mar. Drugs 2016, 14, 84
S8 of S26
Figure S15. HR-MS of compound 2.
Figure S16. 1H-NMR spectrum of compound 2 (300 MHz in DMSO-d6).
Mar. Drugs 2016, 14, 84
S9 of S26
Figure S17. 13C-NMR spectrum of compound 2 (75 MHz in DMSO-d6).
Figure S18. DEPT spectrum of compound 2 (75 MHz in DMSO-d6).
Mar. Drugs 2016, 14, 84
S10 of S26
Figure S19. COSY spectrum of compound 2 (300 MHz in DMSO-d6).
Figure S20. HMQC spectrum of compound 2 (300 MHz in DMSO-d6).
Mar. Drugs 2016, 14, 84
S11 of S26
Figure S21. HMBC spectrum of compound 2 (300 MHz in DMSO-d6).
Figure S22. NOESY spectrum of compound 2 (300 MHz in DMSO-d6).
Mar. Drugs 2016, 14, 84
S12 of S26
Compound 3
Figure S23. UV spectrum of compound 3 in MeOH.
Figure S24. IR spectrum of compound 3.
Mar. Drugs 2016, 14, 84
S13 of S26
Figure S25. HR-MS of compound 3.
Figure S26. 1H-NMR spectrum of compound 3 (300 MHz in CDCl3).
Mar. Drugs 2016, 14, 84
S14 of S26
Figure S27. 13C-NMR spectrum of compound 3 (75 MHz in CDCl3).
Figure S28. DEPT spectrum of compound 3 (75 MHz in CDCl3).
Mar. Drugs 2016, 14, 84
S15 of S26
Figure S29. COSY spectrum of compound 3 (300 MHz in CDCl3).
Figure S30. HMQC spectrum of compound 3 (300 MHz in CDCl3).
Mar. Drugs 2016, 14, 84
S16 of S26
Figure S31. HMBC spectrum of compound 3 (300 MHz in CDCl3).
Figure S32. NOESY spectrum of compound 3 (300 MHz in CDCl3).
Mar. Drugs 2016, 14, 84
S17 of S26
Figure S33. 1H-NMR spectrum of compound 3 (600 MHz in DMSO-d6).
Figure S34. 13C-NMR spectrum of compound 3 (150 MHz in DMSO-d6).
Mar. Drugs 2016, 14, 84
S18 of S26
Figure S35. DEPT spectrum of compound 3 (150 MHz in DMSO-d6).
Figure S36. COSY spectrum of compound 3 (600 MHz in DMSO-d6).
Mar. Drugs 2016, 14, 84
S19 of S26
Figure S37. HMQC spectrum of compound 3 (600 MHz in DMSO-d6).
Figure S38. HMBC spectrum of compound 3 (600 MHz in DMSO-d6).
Mar. Drugs 2016, 14, 84
S20 of S26
Figure S39. HPLC profile of compound 1 (80% MeOH at 210 nm).
Figure S40. HPLC profile of compound 2 (75% MeOH at 210 nm).
Mar. Drugs 2016, 14, 84
S21 of S26
Figure S41. HPLC profile of compound 3 (90% MeOH at 210 nm).
Figure S42. HPLC profile of compound 4 (80% MeOH at 210 nm).
Mar. Drugs 2016, 14, 84
S22 of S26
Figure S43. HPLC profile of compound 5 (95% MeOH at 210 nm).
Figure S44. HPLC profile of compound 6 (95% MeOH at 210 nm).
Mar. Drugs 2016, 14, 84
S23 of S26
Figure S45. HPLC profile of compound 7 (90% MeOH at 210 nm).
Figure S46. HPLC profile of compound 8 (80% MeOH at 210 nm).
Mar. Drugs 2016, 14, 84
S24 of S26
Figure S47. HPLC profile of compound 11 (90% MeOH at 210 nm).
Figure S48. HPLC profile of compound 12 (100% MeOH at 280 nm).
Mar. Drugs 2016, 14, 84
S25 of S26
Figure S49. HPLC profile of compound 13 (90% MeOH at 210nm). Table S 1. Characteristics of compounds 1–8, 11 and 12.
Compounds 1 2 3 4 5 6 7 8 11 12 13
Retention Time (min) 11.773 10.004 19.003 11.376 9.657 13.524 9.406 19.227 15.686 15.803 22.797
Purity 97.60% 98.97% 99.00% 96.805% 99.09% 99.12% 93.57% 98.87% 98.07% 97.893 93.774
Wavelength 210 210 210 210 210 210 210 210 210 280 210
Mar. Drugs 2016, 14, 84
S26 of S26
Table S 2. 13C-NMR data (δ) of 4–13 (75 MHz).
No. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
4a 31.2 32.5 65.9 40.2 74.5 72.1 119.5 139.7 42.3 36.7 27.7 39.0 43.0 54.2 22.6 27.7 55.3 12.1 17.7 40.1 20.9 135.7 130.5 47.2 70.7 26.0 28.3 15.0 a
5a 31.2 32.5 66.0 40.0 74.5 72.2 119.5 139.7 42.3 36.6 21.3 38.9 43.0 54.2 22.6 27.8 55.3 12.0 17.7 40.0 21 135.4 131.4 42.0 32.5 19.5 19.8 17.3
6 a,* 31.4 30.9 65.6 39.2 74.5 69.1 120.6 139.7 42.6 38.1 20.6 38.9 43.1 54.2 22.4 27.9 55.2 12.0 17.4 39.8 21 135.4 131.4 41.9 32.5 19.5 19.8 17.3
7a 26.9 31.0 65.8 40.2 73.7 71.6 120.3 141.1 77.3 40.0 26.9 35.0 43.3 50.1 22.6 27.8 55.4 11.7 21.4 39.8 21.0 135.5 131.4 42.1 32.5 19.5 19.8 17.4
8b 30.4 31.0 68.8 39.3 65.9 62.8 67.0 127.1 134.7 38.2 23.6 35.9 42.3 49.8 24.1 29.2 53.8 11.5 23.0 40.6 21.2 135.8 132.2 43.0 33.3 19.9 20.2 17.9
9b 31.1 32.2 68.7 39.6 67.8 61.3 65.1 125.2 38.7 35.8 19.0 36.6 42.9 152.5 24.9 27.2 56.8 17.6 16.5 39.3 21.2 135.3 132.2 42.8 33.1 19.7 20.0 18.1
10 a,* 30.7 31.0 65.1 40.5 74.5 77.9 71.6 127.2 136.2 40.2 23.0 35.9 41.3 49.4 28.6 22.7 53.9 11.2 22.9 40.0 20.9 135.5 131.3 42.1 32.5 19.5 19.8 17.4
11 a,* 31.7 31 65.1 40.9 76.3 76.0 71.6 127.0 36.4 39.8 18.8 36.6 42.4 147.6 24.7 27.2 56.0 18.0 17.5 38.5 21.2 135.5 131.5 42.1 32.5 19.5 19.8 17.4
12 b 38.6 32.0 70.7 41.0 140.0 116.5 119.8 141.6 46.3 37.2 21.3 39.3 43.0 54.6 23.2 28.5 55.8 12.3 16.5 42.9 21.3 135.8 132.2 40.4 33.3 19.9 20.2 17.8
13 b 31.4 33.2 68.9 39.5 65.1 60.5 63.9 126.9 39.8 34.9 19.5 37.3 43.8 151.9 26.1 28.2 55.6 17.9 17.1 40.6 21.3 135.4 132.5 43.1 33.3 19.9 20.2 17.9
Measured in DMSO-d6; b Measured in CDCl3; * Measured in solvent different from literature.
